Added to YB: 2026-04-28
Pitch date: 2026-04-24
GRCE [bullish]
Grace Therapeutics, Inc.
-7.3%
current return
Author Info
BioEquity Watch is a free, independent publication offering in-depth analysis of biotech and pharmaceutical companies, focused on market-relevant research, IPOs, and drug development pipelines. Sign up for the newsletter.
Company Info
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada.
Market Cap
$35.6M
Pitch Price
$2.33
Price Target
8.00 (+248%)
Dividend
N/A
EV/EBITDA
-1.51
P/E
-6.02
EV/Sales
N/A
Sector
Pharmaceuticals
Category
special_situation
DD: Grace Pharmaceuticals ($GRCE)
GRCE: IV nimodipine for aSAH via proprietary nanoparticle tech. CRL on CMC/leachables, no new trials needed. STRIVE-ON: 19% less hypotension vs oral, 54% vs 8% RDI>95% (46pt delta). 7yr orphan exclusivity, patents to 2043. Peak $320M sales, 40% penetration, 4x multiple=$1.2B EV. 70% PoS on CMC fix. $19M cash, 18mo runway to Q3'27. PT $8 (+256%) on 2027 launch, Type A Jun'26, NDA Aug'26, PDUFA Feb'27.
Read full article (6 min)